Quick Answer
Aptevo Therapeutics Inc. reported Total Revenue of $3.11 million for fiscal year 2022.
Aptevo Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $3.11M -74.7% |
$12.29M +185.3% |
$4.31M -86.7% |
| Revenue (ASC 606) | — | — | — | $3.11M -74.7% |
$12.29M +185.3% |
$4.31M -86.7% |
| Net Income | -$25.97M -7.6% |
-$24.13M -38.6% |
-$17.41M -316.9% |
$8.03M +128.2% |
-$28.46M -60.3% |
-$17.75M +56.1% |
| Diluted EPS | -$87.27 +99.7% |
-$31460.23 -1257.9% |
-$2316.83 -147668.8% |
$1.57 +125.9% |
-$6.07 | — |
| Total Assets | $27.19M +74.4% |
$15.59M -37.2% |
$24.84M -27.4% |
$34.22M -39.6% |
$56.60M +5.7% |
$53.55M +0.3% |
| Cash and Equivalents | $21.62M +148.1% |
$8.71M -48.5% |
$16.90M -25.3% |
$22.64M -49.7% |
$45.04M +12.7% |
$39.98M +221.2% |
| Long-Term Debt | — | — | — | $1.46M -60.7% |
$3.71M | — |
| Stockholders Equity | $17.38M +265.5% |
$4.75M -61.1% |
$12.22M -32.0% |
$17.97M +1378.1% |
$1.22M -92.7% |
$16.59M +40.1% |
| R&D Expense | $14.54M +1.1% |
$14.38M -16.0% |
$17.11M -4.3% |
$17.88M -5.9% |
$18.99M +6.4% |
$17.85M -27.9% |
| Operating Income | -$26.31M -7.0% |
-$24.60M +14.8% |
-$28.88M -0.8% |
-$28.64M -33.8% |
-$21.40M +22.2% |
-$27.49M +32.9% |
| Shares Outstanding | 997,830 +24531.7% |
4,051 -66.1% |
11,958 -99.8% |
6.47M +32.0% |
4.90M +11.0% |
4.41M +36.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2022 | $3.11M | +28.6% | +0.6% |
| Revenue (ASC 606) | March 31, 2022 | $3.11M | +28.6% | +0.6% |
| Net Income | September 30, 2025 | -$7.55M | -48.0% | -21.7% |
| Diluted EPS | September 30, 2025 | -$2.23 | +99.4% | +73.5% |
| Total Assets | September 30, 2025 | $27.00M | +78.2% | +72.8% |
| Cash and Equivalents | September 30, 2025 | $21.06M | +171.6% | +123.8% |
| Long-Term Debt | December 31, 2022 | $1.46M | -60.7% | -23.8% |
| Stockholders Equity | September 30, 2025 | $17.39M | +293.5% | +166.6% |
| R&D Expense | September 30, 2025 | $4.04M | +30.3% | +21.5% |
| Operating Income | September 30, 2025 | -$7.61M | -46.0% | -22.2% |
| Shares Outstanding | September 30, 2025 | 13.81M | -19.0% | +328.3% |
- Aptevo Therapeutics Inc. reported Total Revenue of $3.11 million for fiscal year 2022.
- Aptevo Therapeutics Inc. showed a decrease of -74.7% in Total Revenue compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Revenue (ASC 606) of $3.11 million for fiscal year 2022.
- Aptevo Therapeutics Inc. showed a decrease of -74.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Net Income of -$25.97 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed a decrease of -7.6% in Net Income compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Diluted EPS of $87.27 per share (loss) for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +99.7% in Diluted EPS compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Total Assets of $27.19 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +74.4% in Total Assets compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Cash and Equivalents of $21.62 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +148.1% in Cash and Equivalents compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Long-Term Debt of $1.46 million for fiscal year 2022.
- Aptevo Therapeutics Inc. showed a decrease of -60.7% in Long-Term Debt compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Stockholders Equity of $17.38 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +265.5% in Stockholders Equity compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported R&D Expense of $14.54 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +1.1% in R&D Expense compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Operating Income of -$26.31 million for fiscal year 2025.
- Aptevo Therapeutics Inc. showed a decrease of -7.0% in Operating Income compared to the prior fiscal year.
- Aptevo Therapeutics Inc. reported Shares Outstanding of 997.8 thousand shares for fiscal year 2025.
- Aptevo Therapeutics Inc. showed an increase of +24531.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: